KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Evolent Health (EVH) EBIAT (2016 - 2026)

Evolent Health has reported EBIAT over the past 12 years, most recently at -$429.1 million for Q4 2025.

  • For Q4 2025, EBIAT fell 1781.99% year-over-year to -$429.1 million; the TTM value through Dec 2025 reached -$534.5 million, down 767.39%, while the annual FY2025 figure was -$534.5 million, 767.39% down from the prior year.
  • EBIAT for Q4 2025 was -$429.1 million at Evolent Health, down from -$20.9 million in the prior quarter.
  • Over five years, EBIAT peaked at $3.1 million in Q4 2021 and troughed at -$429.1 million in Q4 2025.
  • A 5-year average of -$37.9 million and a median of -$18.6 million in 2024 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: surged 128.7% in 2021 and later crashed 1781.99% in 2025.
  • Year by year, EBIAT stood at $3.1 million in 2021, then tumbled by 486.9% to -$11.8 million in 2022, then tumbled by 182.86% to -$33.4 million in 2023, then skyrocketed by 31.75% to -$22.8 million in 2024, then crashed by 1781.99% to -$429.1 million in 2025.
  • Business Quant data shows EBIAT for EVH at -$429.1 million in Q4 2025, -$20.9 million in Q3 2025, and -$19.9 million in Q2 2025.